Phase 1 study of novel anti-platelet agent to overcome pharmacogenomic limitations of clopidogrel

Authors

Anil Pareek (ORCID: https://orcid.org/0000-0002-5048-1629)
Vivek Raut
Nitin Chandurkar
Kumar Naidu

Institutions

Ipca Laboratories (India) (IN)

Publication Details

Journal: Open Heart
Published: 2025-02-01
DOI: https://doi.org/10.1136/openhrt-2024-003088
Citations: 1
Primary Topic: Antiplatelet Therapy and Cardiovascular Diseases
Type: article
Field-Weighted Citation Impact: 1.39

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Phase 1 study of novel anti-platelet agent to overcome pharmacogenomic limitations of clopidogrel

Anil Pareek, Vivek Raut, Nitin Chandurkar, Kumar Naidu

Feb 1, 2025

1 citations

Open Heart

Antiplatelet Therapy and Cardiovascular Diseases

1.39

article

Phase 1 study of novel anti-platelet agent to overcome pharmacogenomic limitations of clopidogrel

Anil Pareek, Vivek Raut, Nitin Chandurkar, Kumar Naidu

February 1, 2025article en

1 citations

Abstract

No abstract available for this paper.

Open HeartVol. 12(1)

Ipca Laboratories (India) (IN)

Good health and well-being

Openalex Percentile: Top 23%

Antiplatelet Therapy and Cardiovascular Diseases

1.39

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.